



(51) International Patent Classification:

A61K 47/60 (2017.01) C08G 83/00 (2006.01)
C08G 69/10 (2006.01) A61P 35/00 (2006.01)
C08G 69/40 (2006.01)

(21) International Application Number:

PCT/EP2018/054420

(22) International Filing Date:

22 February 2018 (22.02.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/461,983 22 February 2017 (22.02.2017) US
62/488,151 21 April 2017 (21.04.2017) US
62/591,823 29 November 2017 (29.11.2017) US

(71) Applicant: ASTRAZENECA AB [SE/SE]; 151 85
Södertälje (SE).(72) Inventors: MCCOULL, William; AstraZeneca R&D,
Macclesfield Cheshire SK10 4TG (GB). ASHFORD, Mar-
ianne, Bernice; AstraZeneca R&D, Macclesfield Cheshire
SK10 4TG (GB). GRANT, Iain; AstraZeneca R&D, Mac-

clesfield Cheshire SK10 4TG (GB). HENNESSY, Ed-
ward, John; AstraZeneca R&D Boston 35 Gatehouse
Drive, Waltham, Massachusetts 02451 (US). SECRIST,
John, Paul; AstraZeneca R&D Boston 35 Gatehouse Drive,
Waltham, Massachusetts 02451 (US). OWEN, David;
Starpharma Pty Limited 4-6 Southhampton Cresent, Ab-
botsford, Victoria 3067 (AU). KELLY, Brian; Starpharma
Pty Limited 4-6 Southhampton Cresent, Abbotsford, Victoria
3067 (AU). GIANNIS, Michael; Starpharma Pty Limited
4-6 Southhampton Cresent, Abbotsford, Victoria 3067 (AU).

(74) Agent: STORM, Peter, Jan; AstraZeneca Intellectual
Property Milstein Building, Granta Park, Cambridge Cam-
bridgeshire CB21 6GH (GB).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: THERAPEUTIC DENDRIMERS





Figure 1

(57) Abstract: Disclosed are dendrimers of formula (I); and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions comprising the dendrimer of formula (I) and methods of using the same for treating cancer.

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*